Sucampo Pharmaceuticals (SCMP) Given a $23.00 Price Target at Maxim Group
Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals (NASDAQ:SCMP) in a research report sent to investors on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
“Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis ).”,” the firm’s analyst wrote.
SCMP has been the subject of several other reports. B. Riley boosted their target price on shares of Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a buy rating in a research note on Wednesday. Mizuho cut shares of Sucampo Pharmaceuticals from a buy rating to a neutral rating and decreased their target price for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. UBS reduced their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a research report on Thursday, October 12th. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 3rd. Finally, BidaskClub upgraded shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $16.60.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm had revenue of $61.27 million during the quarter, compared to analysts’ expectations of $58.05 million. During the same period in the previous year, the business posted $0.30 EPS. The business’s revenue was up 5.9% compared to the same quarter last year. analysts forecast that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.
In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.13% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Louisiana State Employees Retirement System raised its position in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Sucampo Pharmaceuticals in the second quarter valued at about $117,000. Pinnacle Associates Ltd. acquired a new stake in shares of Sucampo Pharmaceuticals in the second quarter valued at about $122,000. Trexquant Investment LP acquired a new stake in shares of Sucampo Pharmaceuticals in the third quarter valued at about $122,000. Finally, SG Americas Securities LLC raised its position in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 631 shares during the last quarter. Institutional investors and hedge funds own 65.31% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.